Supplementary tables for "Cutaneous T-cell lymphoma following dupilumab use: A systematic review"

In this systematic review, we aimed to evaluate reported cases of CTLC following dupilumab use and identify characteristics, histologic findings, and timeline of CTCL development. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines was performed using PubMed and Embase databases (Figure 1). Key search terms were: “mycosis fungoides and dupilumab”, “cutaneous T cell lymphoma and dupilumab”, “sezary and dupilumab”. Additional relevant studies were identified using the reference lists from the included articles. Studies reporting at least one patient who developed CTCL, such as mycosis fungoides (MF) or sezary syndrome (SS), after dupilumab treatment for an initial diagnosis other than CTCL, or studies demonstrating exacerbation of CTCL with dupilumab were included. Letters from the editor and cases reporting clinical improvement of MF or SS after dupilumab therapy were excluded. Two reviewers (A.P. and A.E.) independently assessed the articles. Data extracted included: study type, patient demographics, preliminary diagnosis, initial treatment, duration of dupilumab treatment, clinical signs and symptoms, sites involved, body surface area involved, TNM classification/tumor stage, pre- and post-dupilumab histopathologic features, time to biopsy after dupilumab, immunohistochemical phenotype, TCR gene rearrangement, final diagnosis, treatment, and clinical outcome.